A61P 31 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics

Patents for A61P 31 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics (179,784)
10/2011
10/04/2011	US8030445 Glycopeptide derivative
10/04/2011	US8030444 Microbicidal compositions comprising human CD38 polypeptides derived from the extracellular membrane-proximal region
10/04/2011	US8030336 Nicotinamide-based kinase inhibitors
10/04/2011	US8030333 Benzimidazole compound crystal
10/04/2011	US8030296 Oestrogen-17-sulphamates as inhibitors of steroid sulphatase
10/04/2011	US8029823 Controlled release and taste masking oral pharmaceutical composition
10/04/2011	US8029803 Chimeric antigens for eliciting an immune response
10/04/2011	US8029798 Multivalent vaccine composition with mixed carrier
10/04/2011	US8029796 Therapeutic anti-cytomegalovirus compounds
10/04/2011	US8029793 Anticancer agents; rheumatic diseases; osteoporosis; antiinflammatory agents; cloning genes
10/04/2011	US8029779 Claims are for a nitrogen oxide sensor electrode and do not match rest of document; Lactobacillus delbrueckii with antifungal activity and use as a probiotic
10/04/2011	US8029778 Methods of using TICAM-1, an adapter protein that binds toll-like receptor 3
10/04/2011	US8029772 Free-flowing anionic surfactant, alkanolamide and electrolytemixture
10/04/2011	CA2669481C Substituted 2-(2,6-dioxopiperidin-3-yl)-phthalimides and -1-oxoisoindolines and method of reducing tnf.alpha. levels
10/04/2011	CA2521038C Polypeptide comprising cell adhesion motif, t cell epitope and b cell epitope for inducing antibody production
10/04/2011	CA2519350C Composition comprising particulate zinc materials having a defined crystallite size
10/04/2011	CA2438520C Phthalazinone-piperidino-derivatives as pde4 inhibitors
10/04/2011	CA2338886C Expression and characterization of hiv-1 envelope protein associated with a broadly reactive neutralizing antibody response
10/04/2011	CA2262819C Monoclonal antibody which agglutinates e. coli having the cs4-cfa/i family protein
10/04/2011	CA2224075C Vectors for the diagnosis and treatment of solid tumors including melanoma
09/2011
09/29/2011	WO2011119853A1 Analogues for the treatment or prevention of flavivirus infections
09/29/2011	WO2011119759A1 Compounds (cystein based lipopeptides) and compositions as tlr2 agonists used for treating infections, inflammations, respiratory diseases etc.
09/29/2011	WO2011119716A2 Flavivirus host range mutations and uses thereof
09/29/2011	WO2011119628A2 Compositions and methods for self-adjuvanting vaccines against microbes and tumors
09/29/2011	WO2011119549A1 Trioxacarcins and uses thereof
09/29/2011	WO2011119517A2 Antimicrobial compositions
09/29/2011	WO2011119062A1 Composition with fungicidal, antimicrobial and virucidal activity (variants)
09/29/2011	WO2011119047A1 Carvacrol/thymol composition for the treatment of salmonid rickettsial septicemia and infectious salmon anemia
09/29/2011	WO2011118779A1 Pharmaceutical composition for treatment and prevention of herpesvirus infections
09/29/2011	WO2011118743A1 Hcv variant with high productivity of infectious hepatitis c virus, and use thereof
09/29/2011	WO2011118683A1 Patch for medical use
09/29/2011	WO2011117886A1 Bispecific monoclonal antibody capable of cross reacting with lethal factor (lf) and edema factor (ef), and neutralizing edema toxin (et) as well as lethal toxin (lt) of bacillus anthracis
09/29/2011	WO2011117848A1 Full-length immunoglobulins of the igg isotvpe capable of recognizing a heterosubtvpe neutralizing epitope on the hemagglutinin stem region and their use as anti-influenza medicament
09/29/2011	WO2011117708A1 Antituberculosis compositions of byttneria species
09/29/2011	WO2011117424A1 Viral inhibitor compositions for in vivo therapeutic use comprising a combination of (-) -carvone, geraniol and a further essential oil component
09/29/2011	WO2011117408A1 Hiv vaccine
09/29/2011	WO2011117353A1 Bivalent antisense oligonucleotides
09/29/2011	WO2011116663A1 2',2-dithiazol non-nucleoside compounds, preparation methods, pharmaceutical compositions and uses as hepatitis virus inhibitors thereof
09/29/2011	WO2011095764A3 Antimicrobial compounds
09/29/2011	WO2011080132A3 Compounds, compositions and methods for controlling biofilms
09/29/2011	WO2011063085A3 Biofilm disruptive compositions
09/29/2011	WO2011056899A3 Chimeric rsv-f polypeptide and lentivirus or alpha-retrovirus gag-based vlps
09/29/2011	WO2011056486A3 Devices, methods, and composition for controlling infections
09/29/2011	WO2011055979A3 Antiviral composition containing an aleurites fordii or daphne kiusiana extract or a fraction thereof as an active ingredient
09/29/2011	WO2011044570A3 Recombinant antibodies against h1n1 influenza
09/29/2011	WO2011034953A3 Lassa virus-like particles and methods of production thereof
09/29/2011	WO2011022725A9 Mimotopes of hiv and uses thereof
09/29/2011	US20110238016 Drug delivery to a joint
09/29/2011	US20110238003 Method for systemic drug delivery through the nail
09/29/2011	US20110238000 Polymer-conjugated albumin hydrogels for controlled release of therapeutic agents
09/29/2011	US20110237679 Novel antiviral compounds, compositions, and methods of use
09/29/2011	US20110237676 Spermicidal and microbicidal compositions
09/29/2011	US20110237657 Transport-Mediating Colloidal Pharmaceutical Compounds
09/29/2011	US20110237651 Treatment of erythropoietin (epo) related diseases by inhibition of natural antisense transcript to epo
09/29/2011	US20110237650 Treatment of vascular endothelial growth factor (vegf) related diseases by inhibition of natural antisense transcript to vegf
09/29/2011	US20110237649 Treatment of sirtuin 1 (sirt1) related diseases by inhibition of natural antisense transcript to sirtuin 1
09/29/2011	US20110237636 Hepatitis C Virus Inhibitors
09/29/2011	US20110237633 Small molecule modulators of hepatocyte growth factor (scatter factor) activity
09/29/2011	US20110237621 Macrocyclic Inhibitors of Hepatitis C Virus
09/29/2011	US20110237598 New compounds
09/29/2011	US20110237596 Heteroaryl-substituted urea modulators of fatty acid amide hydrolase
09/29/2011	US20110237586 Biaryl compositions and methods for modulating a kinase cascade
09/29/2011	US20110237579 Inhibitors of hcv ns5a
09/29/2011	US20110237577 Bicyclic peptidomimetic inhibitors of aspartyl-proteases for the treatment of infectious diseases
09/29/2011	US20110237574 Use of modified pyrimidine compounds to promote stem cell migration and proliferation
09/29/2011	US20110237555 Use of 2,5-dihydroxybenzene compounds and derivatives for the treatment of rosacea
09/29/2011	US20110237547 Pharmaceutical compositions for the treatment of fungal infections
09/29/2011	US20110237544 Novel Pharmaceutical Agents Containing Carbohydrate Moieties And Methods Of Their Preparation And Use
09/29/2011	US20110237534 Methods for treating gastrointestinal diseases
09/29/2011	US20110237531 Method for producing sophorose lipid
09/29/2011	US20110237530 Anti-xdr-tb drug, anti-mdr-tb drug, and combination anti-tuberculosis drug
09/29/2011	US20110237501 Detection of Mutations in a Gene Associated with Resistance to Viral Infection, OAS1
09/29/2011	US20110237500 Cecropin-magainin hybrid peptides
09/29/2011	US20110237499 Hybrid tripyrrole-octaarginine compounds and their use as medicament in the treatment of cancer and microbial illnesses
09/29/2011	US20110237496 Antinecrotic activity of alpha 1-antitrypsin
09/29/2011	US20110236859 Oral care composition containing oxidase enzyme
09/29/2011	US20110236507 Inhibition of dna polymerases to augment chemotherapeutic and antimicrobial agents
09/29/2011	US20110236504 Versatile disinfectant
09/29/2011	US20110236501 Injectable dual delivery allograph bone/polymer composite for treatment of open fractures
09/29/2011	US20110236494 Ciprofloxacin oral suspension
09/29/2011	US20110236490 Treatment or prevention of viral infection by chlorination
09/29/2011	US20110236489 Vaccine adjuvant combinations
09/29/2011	US20110236485 Shell and core dosage form approaching zero-order drug release
09/29/2011	US20110236484 Genus-Wide Chlamydial Peptide Vaccine Antigens
09/29/2011	US20110236482 Composition For The Prevention And Treatment Of Viral Infections
09/29/2011	US20110236478 Co-crystals and pharmaceutical formulations comprising the same
09/29/2011	US20110236469 Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
09/29/2011	US20110236468 Vaccine compositions
09/29/2011	US20110236454 Injectable drug delivery formulation
09/29/2011	US20110236441 Antimicrobial substrates and uses thereof
09/29/2011	US20110236439 Immediate release formulations of 1-aminocyclohexane compounds, memantine and neramexane
09/29/2011	US20110236437 Nanoparticles and methods of use
09/29/2011	US20110236434 Polymorphic Forms of ST-246 and Methods of Preparation
09/29/2011	US20110236433 Wound care device
09/29/2011	US20110236430 Method for controlling toxicity of metallic particle and low-toxicity composite of metallic nanoparticle and inorganic clay
09/29/2011	US20110236429 Small Cationic Antimicrobial Peptides
09/29/2011	US20110236428 Combination therapy with peptide epoxyketones
09/29/2011	US20110236425 Anthrax vaccine formulation and uses thereof
09/29/2011	US20110236423 Immunogenic agents against burkholderia pseudomallei and/or burkholderia mallei, comprising lipopolysaccharide, capsular polysaccharide and/or proteins from burkholderia pseudomallei
09/29/2011	US20110236422 Variants of hepatitis b virus with resistance to anti-viral nucleoside agents and applications thereof

1 ... 370 371 372 373 374 375 376 377 378 379 380 381 382 383 384 385 386 387 388 389 390 ... 1798